Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids

Lange's handbook of chemistry

Lange, N. A., & Speight, J. G. (1992) · Choice Reviews Online · doi:10.5860/choice.30-1849 · Cited by 7,163

STRUCTURE AND FUNCTIONS OF THE 20S AND 26S PROTEASOMES

Coux, O., Tanaka, K., & Goldberg, A. L. (1996) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.65.070196.004101 · Cited by 2,438

Structure of 20S proteasome from yeast at 2.4Å resolution

Groll, M., Ditzel, L., Löwe, J., Stock, D., Bochtler, M., Bartunik, H. D., & Huber, R. (1997) · Nature · doi:10.1038/386463a0 · Cited by 2,265

Crystal Structure of the 20 S Proteasome from the Archaeon T. acidophilum at 3.4 Å Resolution

Löwe, J., Stock, D., Jap, B. K., Zwickl, P., Baumeister, W. P., & Huber, R. (1995) · Science · doi:10.1126/science.7725097 · Cited by 1,540

Inhibition of the serine proteases leukocyte elastase, pancreatic elastase, cathepsin G, and chymotrypsin by peptide boronic acids.

Kettner, C. A., & Shenvi, A. B. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42521-x · Cited by 294

The selective inhibition of thrombin by peptides of boroarginine.

Kettner, C. A., Mersinger, L. J., & Knabb, R. M. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44751-x · Cited by 254

Inhibition of serine proteases by peptidyl fluoromethyl ketones

Imperiali, B., & Abeles, R. H. (1986) · Biochemistry · doi:10.1021/bi00361a005 · Cited by 248

R-1-Acetamido-2-phenylethaneboronic acid. A specific transition-state analog for chymotrypsin

Matteson, D. S., Sadhu, K. M., & Lienhard, G. E. (1981) · Journal of the American Chemical Society · doi:10.1021/ja00407a051 · Cited by 153

Design, synthesis, and kinetic evaluation of a unique class of elastase inhibitors, the peptidyl .alpha.-ketobenzoxazoles, and the x-ray crystal structure of the covalent complex between porcine pancreatic elastase and Ac-Ala-Pro-Val-2-benzoxazole

Edwards, P. D., Meyer, E. F., Vijayalakshmi, J., Tuthill, P. A., Andisik, D., Gomes, B. C., & Strimpler, A. M. (1992) · Journal of the American Chemical Society · doi:10.1021/ja00031a046 · Cited by 145

Kinetic Characterization of the Chymotryptic Activity of the 20S Proteasome

Stein, R. L., Melandri, F. D., & Dick, L. R. (1996) · Biochemistry · doi:10.1021/bi952262x · Cited by 138

The Future of Boron in Medicinal Chemistry: Therapeutic and Diagnostic Applications

Draganov, A. B., Wang, D., & Wang, B. (2014) · Topics in medicinal chemistry · doi:10.1007/7355_2014_65 · Cited by 20

Harnessing Proteasome Dynamics and Allostery in Drug Design

Gaczynska, M. E., & Osmulski, P. A. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5816 · Cited by 19

Novel CADD-based peptidyl vinyl ester derivatives as potential proteasome inhibitors

Mou, K., Xu, B., Ma, C., Yang, X., Zou, X., Lü, Y., & Xu, P. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.12.077 · Cited by 19

Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence

Russo, A. D., Fratto, M. E., Bazan, V., Schiró, V., Agnese, V., Cicero, G., Vincenzi, B., Tonini, G., & Santini, D. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.12.1571 · Cited by 19

Assays for Proteasome Inhibition

Elliott, P. J., Soucy, T. A., Pien, C. S., Adams, J., & Lightcap, E. S. (2003) · Humana Press eBooks · doi:10.1385/1-59259-380-1:163 · Cited by 19

Several effects of boron are induced by uncoupling steroid hormones from their transporters in blood

Bello, M., Guadarrama-García, C., Velasco-Silveyra, L. M., Farfán‐García, E. D., & Soriano-Ursua, M. A. (2018) · Medical Hypotheses · doi:10.1016/j.mehy.2018.06.024 · Cited by 18

Differential regulation of BIRC2 and BIRC3 expression by inflammatory cytokines and glucocorticoids in pulmonary epithelial cells

Thorne, A. J., Bansal, A., Necker‐Brown, A., Mostafa, M., Gao, A., Georgescu, A., Kooi, C., Leigh, R., & Newton, R. C. (2023) · PLoS ONE · doi:10.1371/journal.pone.0286783 · Cited by 18

Facile Synthesis of Vinyl Boronate Esters via Dehydrogenative Borylation of Alkenes Enabled by a Co-MOF Catalyst: An Additive-Free Approach

Basappa, S., Prakash, A., Talekar, S. S., Mane, M. V., & Bose, S. K. (2024) · ACS Catalysis · doi:10.1021/acscatal.3c05742 · Cited by 18

Therapeutic Landscape of Carfilzomib and Other Modulators of the Ubiquitin-Proteasome Pathway

Mitsiades, C. S. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.5748 · Cited by 18

Proteasome proteolytic profile is linked to Bcr-Abl expression

Crawford, L., Windrum, P., Magill, L., Melo, J. V., McCallum, L. M. R., McMullin, M. F., Ovaa, H., Walker, B., & Irvine, A. E. (2009) · Experimental Hematology · doi:10.1016/j.exphem.2008.11.004 · Cited by 18

Proteasome inhibition activates the transport and the ectodomain shedding of TNF-α receptors in human endothelial cells

Peiretti, F., Canault, M., Bernot, D., Bonardo, B., Deprez, P., Juhan-Vague, I., & Nalbone, G. (2005) · Journal of Cell Science · doi:10.1242/jcs.01696 · Cited by 18

Proteasome inhibitors

Iqbal, M. A., & Ator, M. A. (2000) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8462-4_2 · Cited by 18

Optimization and Evaluation of 5‐Styryl‐Oxathiazol‐2‐one Mycobacterium tuberculosis Proteasome Inhibitors as Potential Antitubercular Agents

Russo, F., Gising, J., Åkerbladh, L., Roos, A. K., Naworyta, A., Mowbray, S. L., Sokolowski, A., Henderson, I., Alling, T., Bailey, M. A., et al. (2015) · ChemistryOpen · doi:10.1002/open.201500001 · Cited by 17

PLZF and its fusion proteins are pomalidomide-dependent CRBN neosubstrates

Shimizu, N., Asatsuma‐Okumura, T., Yamamoto, J., Yamaguchi, Y., Handa, H., & Ito, T. (2021) · Communications Biology · doi:10.1038/s42003-021-02801-y · Cited by 17

Synthesis and Evaluation of Macrocyclic Peptide Aldehydes as Potent and Selective Inhibitors of the 20S Proteasome

Wilson, D. L., Meininger, I., Strater, Z. M., Steiner, S., Tomlin, F. M., Wu, J. J., Jamali, H., Krappmann, D., & Götz, M. G. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00401 · Cited by 17

Molecular mechanisms for synergistic effect of proteasome inhibitors with platinum-based therapy in solid tumors

Chao, A., & Wang, T. (2016) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2015.12.004 · Cited by 17

Recyclable Copper Nanoparticles‐Catalyzed Hydroboration of Alkenes and β‐Borylation of α,β‐Unsaturated Carbonyl Compounds with Bis(Pinacolato)Diboron

Shegavi, M. L., Saini, S., Bhawar, R., Vishwantha, M. D., & Bose, S. K. (2021) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.202001616 · Cited by 17

1,4-Azaborines: Origin, Modern Synthesis, and Applications as Optoelectronic Materials

Lim, H. N., Hong, W. P., & Shin, I. (2021) · Synthesis · doi:10.1055/s-0040-1719851 · Cited by 17

Variation in Drug Sensitivity of Malignant Mesothelioma Cell Lines with Substantial Effects of Selenite and Bortezomib, Highlights Need for Individualized Therapy

Szulkin, A., Nilsonne, G., Mundt, F., Wasik, A. M., Souri, P., Hjerpe, A., & Dobra, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065903 · Cited by 17

Proteasomal inhibition stabilizes topoisomerase IIα protein and reverses resistance to the topoisomerase II poison ethonafide (AMP-53, 6-ethoxyazonafide)

Congdon, L. M., Pourpak, A., Escalante, A. M., Dorr, R. T., & Landowski, T. H. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.10.026 · Cited by 17

Metabolism and Action of Proteasome Inhibitors in Primary Human Hepatocytes

Lee, C., Kumar, V., Riley, R. I., & Morgan, E. T. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.035501 · Cited by 17

The therapeutic potential of microbial proteasome inhibitors

Momose, I., & Kawada, M. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.11.013 · Cited by 17

Syrbactin Structural Analog TIR-199 Blocks Proteasome Activity and Induces Tumor Cell Death

Bachmann, A. S., Opoku‐Ansah, J., Ibarra‐Rivera, T. R., Yco, L., Sudhakar, A., Roberts, C. C., Chang, C. A., & Pirrung, M. C. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.710053 · Cited by 17

Study of chemoselective asymmetric hydrogenation of (1-bromo-1-alkenyl)boronic esters with iridium–PˆN complexes

Roseblade, S. J., Smilović, I. G., & Časar, Z. (2014) · Tetrahedron · doi:10.1016/j.tet.2014.02.065 · Cited by 17

Novel Cell-Penetrating Peptide Conjugated Proteasome Inhibitors: Anticancer and Antifungal Investigations

Patel, K. D., Zoysa, G. H. D., Kanamala, M., Patel, K., Pilkington, L. I., Barker, D. L. A., Reynisson, J., Wu, Z., & Sarojini, V. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01694 · Cited by 17

The Potential Role of Boron in the Modulation of Gut Microbiota Composition: An In Vivo Pilot Study

Sentürk, N. B., Kasapoğlu, B., Şahin, E., Özcan, O., Ozansoy, M., Ozansoy, M. B., Si̇yah, P., Sezerman, O. U., & Şahi̇n, F. (2024) · Pharmaceuticals · doi:10.3390/ph17101334 · Cited by 17

Cyclization of peptoids by formation of boronate esters

Chirayil, S., & Luebke, K. J. (2011) · Tetrahedron Letters · doi:10.1016/j.tetlet.2011.12.002 · Cited by 16

Capillary electrophoresis for screening of 20S proteasome inhibitors

Chen, W., Mou, K., Xu, B., Ling, X., Cui, J., & Xu, P. (2009) · Analytical Biochemistry · doi:10.1016/j.ab.2009.07.020 · Cited by 16

Low levels of mutant ubiquitin are degraded by the proteasome in vivo

van Tijn, P., Verhage, M. C., Hobo, B., van Leeuwen, F. W., & Fischer, D. F. (2010) · Journal of Neuroscience Research · doi:10.1002/jnr.22396 · Cited by 16

Chemical proteasome inhibition as a novel animal model of inner retinal degeneration in rats

Kageyama, M., Ota, T., Sasaoka, M., Katsuta, O., & Shinomiya, K. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217945 · Cited by 16

Regioselective synthesis of ortho -iodobiphenylboronic acid derivatives: a superior catalyst for carboxylic acid activation

Al‐Zoubi, R. M., Al‐Jammal, W. K., & McDonald, R. (2020) · New Journal of Chemistry · doi:10.1039/c9nj05708k · Cited by 16

Bortezomib-loaded lipidic-nano drug delivery systems; formulation, therapeutic efficacy, and pharmacokinetics

Mahmoudian, M., Valizadeh, H., Löbenberg, R., & Zakeri‐Milani, P. (2021) · Journal of Microencapsulation · doi:10.1080/02652048.2021.1876175 · Cited by 17

Nature of Irreversible Inhibition of Human 20S Proteasome by Salinosporamide A. The Critical Role of Lys–Asp Dyad Revealed from Electrostatic Effects Analysis

Serrano-Aparicio, N., Moliner, V., & Świderek, K. (2021) · ACS Catalysis · doi:10.1021/acscatal.0c05313 · Cited by 17

A Boron-Containing Compound Acting on Multiple Targets Against Alzheimer’s Disease. Insights from Ab Initio and Molecular Dynamics Simulations

Ritacca, A. G., Ritacco, I., Dabbish, E., Russo, N., Mazzone, G., & Sicilia, E. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00262 · Cited by 16

Iridium‐Catalyzed Chemoselective and Enantioselective Hydrogenation of (1‐Chloro‐1‐Alkenyl) Boronic Esters

Smilović, I. G., Casas‐Arcé, E., Roseblade, S. J., Nettekoven, U., Zanotti‐Gerosa, A., Kovačevič, M., & Časar, Z. (2011) · Angewandte Chemie · doi:10.1002/ange.201106262 · Cited by 16

Effects of B2O3 (boron trioxide) on colon cancer cells: our first-step experience and in vitro results

Albuz, Ö., DÜLGER, D., Tunalı, B. Ç., AYDIN, F., Yalçın, S., & Türk, M. (2019) · TURKISH JOURNAL OF BIOLOGY · doi:10.3906/biy-1901-34 · Cited by 16

The Proteasome as a Novel Target for the Treatment of Breast Cancer1

Adams, J. (2002) · Breast Disease · doi:10.3233/bd-2002-15107 · Cited by 16

Proteasome inhibition as a therapeutic strategy for hematologic malignancies

Mitsiades, C. S., Mitsiades, N., Hideshima, T., Richardson, P. G. G., & Anderson, K. C. (2005) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.5.3.465 · Cited by 16

The emerging role of bortezomib in the treatment of indolent non-hodgkin’ and mantle cell lymphomas

O’Connor, O. A. (2004) · Current Treatment Options in Oncology · doi:10.1007/s11864-004-0018-2 · Cited by 16

Serine phosphorylation facilitates protein degradation by the human mitochondrial ClpXP protease

Feng, Y., Goncalves, M. M., Jitkova, Y., Keszei, A. F. A., Yan, Y., Sarathy, C., St‐Germain, J. R., Kenney, T. M. G., Tcheng, M., Trudel, V., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2422447122 · Cited by 15

Different Strategies to Overcome Resistance to Proteasome Inhibitors—A Summary 20 Years after Their Introduction

Tyrna, P., Procyk, G., Szeleszczuk, Ł., & Młynarczuk-Biały, I. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168949 · Cited by 15

An Historic Perspective of Proteasome Inhibition

Esseltine, D.-L. W., & Mulligan, G. (2012) · Seminars in Hematology · doi:10.1053/j.seminhematol.2012.04.009 · Cited by 15

Pharmacodynamics and pharmacokinetics of proteasome inhibitors for the treatment of multiple myeloma

Baljević, M., & Orlowski, R. Z. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1621839 · Cited by 15

In vivo imaging of proteasome inhibition using a proteasome‐sensitive fluorescent reporter

Momose, I., Tatsuda, D., Ohba, S., Masuda, T., Ikeda, D., & Nomoto, A. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02352.x · Cited by 15

Inhibitory effects of delphinidin and luteolin on genotoxicity induced by K2B3O3F4OH) in human lymphocytes in vitro

Hadžić, M., Haverić, S., Haverić, A., & Galić, B. (2015) · Biologia · doi:10.1515/biolog-2015-0066 · Cited by 15

Archaeal proteasomes: Proteolytic nanocompartments of the cell

Maupin-furlow, J. A., Kaczowka, S. J., Ou, M. S., & Wilson, H. L. (2001) · Advances in applied microbiology · doi:10.1016/s0065-2164(01)50008-8 · Cited by 15

Proteasome inhibitors: a therapeutic strategy for haematological malignancy

Crawford, L. (2008) · Frontiers in bioscience · doi:10.2741/3005 · Cited by 15

Stereoselective Synthesis of Deuterated β-Cyclohexenylserine, a Biosynthetic Intermediate of the Salinosporamides

Deska, J., Hähn, S., & Kazmaier, U. (2011) · Organic Letters · doi:10.1021/ol201120k · Cited by 14

Novel Class of Proteasome Inhibitors: In Silico and In Vitro Evaluation of Diverse Chloro(trifluoromethyl)aziridines

Ielo, L., Patamia, V., Citarella, A., Efferth, T., Shahhamzehei, N., Schirmeister, T., Stagno, C., Langer, T., Rescifina, A., Micale, N., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012363 · Cited by 14

TNFα increases the degradation of pyruvate dehydrogenase kinase 4 by the Lon protease to support proinflammatory genes

Boutagy, N. E., Fowler, J. W., Grabińska, K. A., CARDONE, R. L., Sun, Q., Vazquez, K. R., Whalen, M. B., Zhu, X., Chakraborty, R., Martin, K. A., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2218150120 · Cited by 14

Antitumor effects of tyropeptin‐boronic acid derivatives: New proteasome inhibitors

Momose, I., Abe, H., Watanabe, T., Ohba, S., Yamazaki, K., Dan, S., Yamori, T., Masuda, T., & Nomoto, A. (2014) · Cancer Science · doi:10.1111/cas.12542 · Cited by 14

Inhibitors of the proteasome stimulate the epithelial sodium channel (ENaC) through SGK1 and mimic the effect of aldosterone

Mansley, M. K., Korbmacher, C., & Bertog, M. (2017) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-017-2060-5 · Cited by 14

Boronate, trifluoroborate, sulfone, sulfinate and sulfonate congeners of oseltamivir carboxylic acid: Synthesis and anti-influenza activity

Hong, B.-T., Cheng, Y. E., Cheng, T.-J. R., & Fang, J. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.12.027 · Cited by 14

Proteasome inhibitors as therapeutic agents

Adams, J. (2003) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.13.1.45 · Cited by 14

Synthesis and reactivity of palladium and platinum diimine complexes containing boronate esters

King, A. S., Nikolcheva, L. G., Graves, C. R., Kaminski, A., Vogels, C. M., Hudson, R. H. E., Ireland, R. J., Duffy, S. J., & Westcott, S. A. (2002) · Canadian Journal of Chemistry · doi:10.1139/v02-145 · Cited by 14

Next generation proteomics with drug sensitivity screening identifies sub-clones informing therapeutic and drug development strategies for multiple myeloma patients

Tierney, C., Bazou, D., Majumder, M. M., Anttila, P. M., Silvennoinen, R. H., Heckman, C. A., Dowling, P., & O’Gorman, P. (2021) · Scientific Reports · doi:10.1038/s41598-021-90149-y · Cited by 13

ZNF574 is a Quality Control Factor For Defective Ribosome Biogenesis Intermediates

Akers, J. F., LaScola, M., Bothe, A., Suh, H., Jung, C., Stolp, Z. D., Ghosh, T., Yan, L. L., Wang, Y., Macurak, M., et al. (2024) · Molecular Cell · doi:10.1016/j.molcel.2025.04.017 · Cited by 15

α‐Keto‐Aldehyd‐Peptide: ein Leitmotiv für die Entwicklung reversibler Proteasominhibitoren

Gräwert, M. A., Gallastegui, N., Stein, M., Schmidt, B., Kloetzel, P., Huber, R., & Groll, M. (2010) · Angewandte Chemie · doi:10.1002/ange.201005488 · Cited by 13

A simplified method for bortezomib determination using dried blood spots in combination with liquid chromatography/tandem mass spectrometry

Guo, Z., Yang, F., van den Anker, J. N., Zheng, Y., & Zhao, W. (2021) · Journal of Chromatography B · doi:10.1016/j.jchromb.2021.122905 · Cited by 13

Proteasome Inhibitors Therapeutic Strategies for Cancer

D’Alessandro, A., Pieroni, L., Ronci, M., D’Aguanno, S., Federici, G., & Urbani, A. (2008) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/157489209787002452 · Cited by 13

Computational Investigation of the Oxidative Deboronation of Boroglycine, H 2 N−CH 2 −B(OH) 2 , Using H 2 O and H 2 O 2

Larkin, J. D., Markham, G. D., Milkevitch, M., Brooks, B. R., & Bock, C. W. (2009) · The Journal of Physical Chemistry A · doi:10.1021/jp904149w · Cited by 13

Synthesis of Lithocholic Acid Derivatives as Proteasome Regulators

Dang, Z., Jung, K., Qian, K., Lee, K., Huang, L., & Chen, C. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml3001962 · Cited by 13

A mechanistic study on the inhibition of α-chymotrypsin by a macrocyclic peptidomimetic aldehyde

Zhang, X., Bruning, J. B., George, J. H., & Abell, A. D. (2016) · Organic & Biomolecular Chemistry · doi:10.1039/c6ob01159d · Cited by 13

Advances in Theoretical Studies on the Design of Single Boron Atom Compounds

Bello, M. (2018) · Current Pharmaceutical Design · doi:10.2174/1381612824666181102142432 · Cited by 13

Elucidation of the Structure and Intermolecular Interactions of a Reversible Cyclic‐Peptide Inhibitor of the Proteasome by NMR Spectroscopy and Molecular Modeling

Stauch, B., Simon, B., Basile, T., Schneider, G., Malek, N. P., Kalesse, M., & Carlomagno, T. (2010) · Angewandte Chemie · doi:10.1002/ange.201000140 · Cited by 13

Chapter 11 Proteinase families and their inhibitors

Mykles, D. L. (2001) · Methods in cell biology · doi:10.1016/s0091-679x(01)66012-6 · Cited by 13

Peptide and Peptide-Like Modulators of 20S Proteasome Enzymatic Activity in Cancer Cells

Garcı́a-Echeverrı́a, C. (2006) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-005-9001-4 · Cited by 15

Tyropeptins, proteasome inhibitors produced by Kitasatospora sp. MK993-dF2

Momose, I., & Watanabe, T. (2017) · The Journal of Antibiotics · doi:10.1038/ja.2017.9 · Cited by 12

Electrochemical Investigation of the Influence of K2[B3O3F4OH] on the Activity of Immobilized Superoxide Dismutase

Herenda, S., Ostojić, J., Hasković, E., Hasković, D., Miloš, M., & Galić, B. (2018) · International Journal of Electrochemical Science · doi:10.20964/2018.04.35 · Cited by 12

Nonselective proteasome inhibitors in multiple myeloma and future perspectives

Gavriatopoulou, M., Malandrakis, P., Ntanasis‐Stathopoulos, I., & Dimopoulos, M. A. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1999411 · Cited by 13

Synthesis of l -cysteine-based boron compounds and their evaluation as proteasome inhibitors

Milani, P., Demasi, M., de Rezende, L., do Amaral, A. T., & Andrade, L. H. (2014) · New Journal of Chemistry · doi:10.1039/c4nj00612g · Cited by 12

Pharmacophore Modeling, Docking Studies, and Synthesis of Novel Dipeptide Proteasome Inhibitors Containing Boron Atoms

Lei, M., Zhao, X., Wang, Z., & Zhu, Y. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci900225s · Cited by 12

Peptidomimetics in cancer chemotherapy

Avendaño, C., & Menéndez, J. C. (2007) · Clinical & Translational Oncology · doi:10.1007/s12094-007-0104-6 · Cited by 12

Proteasome selectivity towards Michael acceptor containing oligopeptide-based inhibitors

van der Linden, W. A., Geurink, P. P., Oskam, C., van der Marel, G. A., Florea, B. I., & Overkleeft, H. S. (2010) · Organic & Biomolecular Chemistry · doi:10.1039/b924134e · Cited by 12

Synthesis and Evaluation of Boron-Containing Heterocyclic Compounds with Antimicrobial and Anticancer Activities

Prates, J. L. B., Silva, S. D. M., Medina‐Alarcón, K. P., dos Santos, K. S., Belizário, J. A., Lopes, J. R., Marin-Dett, F. H., Campos, D. L., Mendes‐Giannini, M. J. S., Fusco‐Almeida, A. M., et al. (2025) · Molecules · doi:10.3390/molecules30051117 · Cited by 11

Bortezomib inhibits C2C12 growth by inducing cell cycle arrest and apoptosis

Xing, S. S., Shen, C., Godard, M. P., Wang, J. J., Yue, Y. Y., Yang, S., Zhao, Q., Zhang, S., Wang, T., Yang, X., et al. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.02.008 · Cited by 11

Oxygen-dependent regulation of E3(SCF)ubiquitin ligases and a Skp1-associated JmjD6 homolog in development of the social amoeba Dictyostelium

Boland, A. W., Gas‐Pascual, E., Nottingham, B. L., van der Wel, H., Daniel, N. G., Sheikh, M. O., Schafer, C. M., & West, C. M. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102305 · Cited by 11

Host Cell Neddylation Facilitates Alphaherpesvirus Entry in a Virus-Specific and Cell-Dependent Manner

Lee, B. H., Tebaldi, G., Pritchard, S. M., & Nicola, A. V. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.03114-22 · Cited by 11

Fresh target for cancer therapy

Deshaies, R. J. (2009) · Nature · doi:10.1038/458709a · Cited by 11

Boronic Acid Group: A Cumbersome False Negative Case in the Process of Drug Design

Katsamakas, S., Papadopoulos, A. G., & Hadjipavlou‐Litina, D. (2016) · Molecules · doi:10.3390/molecules21091185 · Cited by 11

Therapeutic Applications of Peptides against Zika Virus: A Review

Karwal, P., Vats, I. D., Sinha, N., Singhal, A., Sehgal, T., & Kumari, P. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190111115132 · Cited by 11

Steuerung der intrazellulären Proteinmenge durch niedermolekulare Modulatoren des Ubiquitin‐Proteasom‐Systems

Buckley, D. L., & Crews, C. M. (2014) · Angewandte Chemie · doi:10.1002/ange.201307761 · Cited by 11

Use of bortezomib in B-cell non-Hodgkin’s lymphoma

Wang, M. L., Zhou, Y., Zhang, L., Nguyen, C. A., & Romaguera, J. E. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.7.983 · Cited by 11

Management of Relapsed and Relapsed Refractory Myeloma

Kastritis, E., Mitsiades, C. S., Dimopoulos, M. A., & Richardson, P. G. G. (2007) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2007.08.014 · Cited by 11

The Translational Research Working Group Developmental Pathway for Anticancer Agents (Drugs or Biologics)

Schilsky, R. L., Gordon, G., Gilmer, T. M., Courtneidge, S. A., Matrisian, L. M., Grad, O., & Nelson, W. G. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1265 · Cited by 11

Ubiquitin proteasome inhibition and cancer therapy

Shah, S. A., Potter, M. W., & Callery, M. P. (2002) · Surgery · doi:10.1067/msy.2002.121890 · Cited by 11

A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy

Lieu, C. H., Chow, L. Q. M., Pierson, A. S., Eckhardt, S., O’Bryant, C. L., Morrow, M., Tran, Z. V., Wright, J. J., & Gore, L. (2008) · Investigational New Drugs · doi:10.1007/s10637-008-9154-z · Cited by 11

Optimization of a series of dipeptides with a P3 β-neopentyl asparagine residue as non-covalent inhibitors of the chymotrypsin-like activity of human 20S proteasome

Blackburn, C., Barrett, C., Blank, J. L., Bruzzese, F. J., Bump, N. J., Dick, L. R., Fleming, P. E., Garcia, K., Hales, P., Jones, M. D., et al. (2012) · MedChemComm · doi:10.1039/c2md20060k · Cited by 10

The importance of ubiquitin E3 ligases, SCF and APC/C, in human cancers

Bochis, O. V., Fetică, B., Vlad, C. I., Achimaș-Cădariu, P., & Irimie, A. (2015) · Medicine and Pharmacy Reports · doi:10.15386/cjmed-377 · Cited by 10

A Reporter System for Cytosolic Protein Aggregates in Yeast

Romero-Suárez, D., Wulff, T., Rong, Y., Jakočiūnas, T., Yuzawa, S., Keasling, J. D., & Jensen, M. K. (2021) · ACS Synthetic Biology · doi:10.1021/acssynbio.0c00476 · Cited by 10

Drug Discovery and Target Identification against Schistosomiasis: A Reality Check on Progress and Future Prospects

Cheuka, P. M. (2021) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026621666210924101805 · Cited by 11

Pharmacophore modeling technique applied for the discovery of proteasome inhibitors

Pautasso, C., Troia, R., Genuardi, M., & Palumbo, A. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.923838 · Cited by 10

The paradoxical pharmacological mechanisms of lenalidomide and bortezomib in the treatment of multiple myeloma

Wang, B., Duan, J., & Zhou, L. (2021) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001041 · Cited by 10

Ubiquitin- and proteasome-dependent pathway of protein degradation as an emerging therapeutic target

Wójcik, C. (2000) · Emerging Therapeutic Targets · doi:10.1517/14728222.4.1.89 · Cited by 10

RAPID resistance to BET inhibitors is mediated by FGFR1 in glioblastoma

Jermakowicz, A. M., Kurimchak, A., Johnson, K. J., Bourgain‐Guglielmetti, F., Kaeppeli, S., Affer, M., Pradhyumnan, H., Suter, R. K., Walters, W. M., Cepero, M. L., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-60031-8 · Cited by 10

Doxorubicin synergizes bortezomib-induced multiple myeloma cell death by inhibiting aggresome formation and augmenting endoplasmic reticulum/Golgi stress and apoptosis

Yu, C. R., Liao, Y. A., Chiang, C.-Y. N., Chen, J. M., Pan, H.-Y. B., Pan, C.-Y., Jiang, W.-J., Tsai, J.-R., Yang, T., & Teng, C. J. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05920-2 · Cited by 9

Exploring dual electrophiles in peptide-based proteasome inhibitors: carbonyls and epoxides

Xin, B., de Bruin, G., Verdoes, M., Filippov, D. V., van der MAREL, G. A., & Overkleeft, H. S. (2014) · Organic & Biomolecular Chemistry · doi:10.1039/c4ob00893f · Cited by 9

Proteasome inhibition induces developmentally deregulated programs of apoptotic and autophagic cell death duringDrosophila melanogasteroogenesis

Velentzas, P. D., Velentzas, A. D., Mpakou, V., Papassideri, I. S., Stravopodis, D. J., & Margaritis, L. H. (2010) · Cell Biology International · doi:10.1042/cbi20100191 · Cited by 9

Synthesis and stability study of isocyano aryl boronate esters and their synthetic applications

Fang, H.-P., Fu, C.-C., Tai, C., Chang, K.-H., Yang, R., Wu, M., Chen, H.-C., Li, C., Huang, S., Lien, W., et al. (2016) · RSC Advances · doi:10.1039/c5ra27624a · Cited by 9

Mouse genetic background contributes to hepatocyte susceptibility to Fas-mediated apoptosis

Weerasinghe, S. V. W., Park, M.-J., Portney, D. A., & Omary, M. B. (2016) · Molecular Biology of the Cell · doi:10.1091/mbc.e15-06-0423 · Cited by 9

ChemInform Abstract: Potent and Selective Inhibitors of the Proteasome: Dipeptidyl Boronic Acids.

Adams, J., Behnke, M. L., CHEN, S., Cruickshank, A., Dick, L. R., Grenier, L., Klunder, J. M., MA, Y. ‐., Plamondon, L., & Stein, R. L. (1998) · ChemInform · doi:10.1002/chin.199821191 · Cited by 1

α-Aminoboronic Acid Moieties in Boro Dipeptides Modulate Proteasome Subunit Selectivity and Provide Access to Compounds with Potent Anticancer and Anti-Inflammatory Activity

Benedik, N. S., Šterman, A., Smrdel, L., Pajk, S., Gobec, S., Časar, Z., Gobec, M., & Sosič, I. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02548 · Cited by 3

Synthesis, in Vitro and in Vivo Biological Evaluation, and Comprehensive Understanding of Structure−Activity Relationships of Dipeptidyl Boronic Acid Proteasome Inhibitors Constructed from β-Amino Acids

Zhu, Y., Wu, G., Zhu, X., Ma, Y., Zhao, X., Li, Y., Yuan, Y., Yang, J., Yu, S., Shao, F., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1009742 · Cited by 38

Synthesis, in Vitro and in Vivo Biological Evaluation, Docking Studies, and Structure−Activity Relationship (SAR) Discussion of Dipeptidyl Boronic Acid Proteasome Inhibitors Composed of β-Amino Acids

Zhu, Y., Zhu, X., Wu, G., Ma, Y., Li, Y., Zhao, X., Yuan, Y., Yang, J., Yu, S., Shao, F., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901407s · Cited by 39

Design, Synthesis, Biological Evaluation, and Structure−Activity Relationship (SAR) Discussion of Dipeptidyl Boronate Proteasome Inhibitors, Part I: Comprehensive Understanding of the SAR of α-Amino Acid Boronates

Zhu, Y., Zhao, X., Zhu, X., Wu, G., Li, Y., Ma, Y., Yuan, Y., Yang, J., Hu, Y., Ai, L., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9005093 · Cited by 75